Nachrichten zur Gilead Sciences Aktie

Why Gilead Sciences Stock Slipped Today

Gilead Sciences (NASDAQ: GILD) didnt have a bad first quarter, but investors didnt find it inspiring either. After publishing its…

GILD Down on Q1 Earnings and Sales Miss, Oncology Sales Decline

Gilead Sciences Q1 earnings and sales miss estimates on lower oncology drug sales. The stock is trading down.…

Gilead (GILD) Q1 2025 Earnings Call Transcript

Image source: The Motley Fool. DATEThursday, Apr 24, 2025CALL PARTICIPANTSDaniel ODay: Chairman and Chief Executive OfficerJohanna Mercier: Chief Commercial OfficerDietmar Berger:…

Gilead Sciences (GILD) Q1 Earnings and Revenues Lag Estimates

Gilead (GILD) delivered earnings and revenue surprises of -0.55% and 2.46%, respectively, for the quarter ended March 2025. Do the…

Gilead Sciences shares fall as Q1 revenue misses estimates By Investing.com

Gilead Sciences shares fall as Q1 revenue misses estimates…

Gilead reports quarterly profit, revenue flat as cancer sales slow

Gilead Sciences on Thursday reported slightly higher-than-expected quarterly earnings on flat revenue, as higher sales of drugs for HIV and…

Interessante Einstiege finden - BioNTech, BioNxt Solutions, Gilead Sciences, Merck & Co.

Die aggressive Zollpolitik der US-Administration unter US-Präsident Trump hat zu Umschichtungsprozessen bei den Anlegern geführt. So zogen europäische ETF-Anleger über…

Heres Why Gilead Sciences (GILD) is a Strong Value Stock

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Heres why…

Gilead Sciences (GILD) Reports Next Week: Wall Street Expects Earnings Growth

Gilead (GILD) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report.…

Should You Buy, Hold, or Sell GILD Stock Ahead of Q1 Earnings?

Gilead Sciences leading HIV business might face a slowdown in 2025, even though a potential approval of lenacapavir would be…

Gilead Sciences (GILD) Stock Moves -0.74%: What You Should Know

In the latest trading session, Gilead Sciences (GILD) closed at $104.90, marking a -0.74% move from the previous day.…

Is Iovance Biotherapeutics a Millionaire-Maker?

Some investors see a striking similarity between lottery tickets and biotech stocks. In most cases, buying lottery tickets ends up…

Rule Breaker Investing: Essays From Yesterday, Vol. 7

Its time once again to dust off Motley Fool co-founder David Gardners old writings and pull some lessons forward into…

Gilead Sciences (GILD) Increases Yet Falls Behind Market: What Investors Need to Know

In the closing of the recent trading day, Gilead Sciences (GILD) stood at $105.25, denoting a +2% change from the…

2 Top Dividend Stocks That Could Set You Up for Life

With equity markets in shambles due to President Donald Trumps trade policies, now might be as good a time as…

Is Vertex Pharmaceuticals Stock a Buy?

Investors seeking relief from the stock market turbulence at the start of 2025 should take a close look at Vertex…

Gilead Sciences (GILD) Ascends While Market Falls: Some Facts to Note

Gilead Sciences (GILD) reachead $112.39 at the closing of the latest trading day, reflecting a +0.45% change compared to its…

Gilead Sciences (GILD) Ascends But Remains Behind Market: Some Facts to Note

In the most recent trading session, Gilead Sciences (GILD) closed at $111.88, indicating a +0.54% shift from the previous trading…

Gilead Sciences (GILD) Stock Drops Despite Market Gains: Important Facts to Note

The latest trading day saw Gilead Sciences (GILD) settling at $106.67, representing a -0.38% change from its previous close.…

Gilead Sciences (GILD) Suffers a Larger Drop Than the General Market: Key Insights

In the closing of the recent trading day, Gilead Sciences (GILD) stood at $105.87, denoting a -1.53% change from the…

GILD Stock Down on Report of Cut in HIV Prevention Spending

Gilead Sciences takes a hit after a Wall Street Journal reports state that the Trump administration is looking to slash…

Gilead Sciences Aktie: Politische Risiken könnten langfristig problematisch werden

Charlotte (www.aktiencheck.de) - Gilead Sciences-Aktienanalyse der Bank of America (BofA): 1. Einleitung Die BofA hat ihre "buy"-Einstufung für die Aktie von Gilead…

Stocks making the biggest moves midday: Boeing, Nvidia, Autodesk, Gilead Sciences and more

These are the stocks posting the largest moves in midday trading.…

Stocks making the biggest moves premarket: General Mills, Gilead Sciences, Tesla and more

These are the stocks posting the largest moves in premarket trading.…

Gilead Sciences Aktie: Lenacapavir als zukünftiger Wachstumstreiber

New York (www.aktiencheck.de) - Gilead Sciences-Aktienanalyse von Oppenheimer: 1. Hintergrund der Einschätzung Oppenheimer hat die "outperform"-Bewertung für die Aktie von Gilead Sciences…

S&P 500 Sell-Off: Heres Why This ETF May Be the Smartest Way to Invest in the S&P 500 Right Now

The Sun was shining brightly on the U.S. stock market over the past couple of years. Unfortunately, some clouds have…

Gilead und GSK: Massiver Rückschlag droht!

Die beiden Gesellschaften Gilead Sciences und GSK (vormals GlaxoSmithKline) sind die führenden großen Anbieter von HIV-Medikamenten. Doch in den USA…

GILD Stock Trading Close to Its 52-Week High: Should You Buy or Sell?

Gilead Sciences hits a 52-week high buoyed by investor optimism. We believe there is still room for growth and recommend…

The Zacks Analyst Blog Highlights Exelon, Gilead Sciences, Plains All American Pipeline, Sportradar and Cintas

Exelon, Gilead Sciences, Plains All American Pipeline, Sportradar and Cintas are part of the Zacks top Analyst Blog…

GILD Data on Once-Yearly Lenacapavir for HIV Prevention Positive

Gilead Sciences data on two novel, once-yearly formulations of lenacapavir for PrEP support the further development of the drug.…

The Top Nasdaq-100 Stock in 2025 Has Nothing to Do With Artificial Intelligence (AI)

In 2024, technology stocks involved in artificial intelligence (AI) led the Nasdaq-100 index higher, while healthcare stocks struggled due in…

These 3 Attractive Stocks Keep Cruising Higher

Despite recent negativity, several stocks, including Verizon Communications, Gilead Sciences, and Alibaba, have shaken off the woes, showing stability and…

Zacks Investment Ideas feature highlights: Gilead Sciences and Johnson & Johnson

Gilead Sciences and Johnson & Johnson are part of the Zacks Investment Ideas article.…

Is Gilead Sciences (GILD) Stock Outpacing Its Medical Peers This Year?

Here is how Gilead Sciences (GILD) and ANIXA BIOSCIENCES INC (ANIX) have performed compared to their sector so far this…

Buy Gilead Sciences (GILD) Stock at 52-Week Highs?

Medical pioneer Gilead Sciences (GILD) has seen its stock etch out new 52-week highs as the broader market pulled back…

Gilead Sciences Aktie: 132 oder 90 USD? Kursziele und Ratings der Analysten nach Q4-Zahlen auf einen Blick - Aktiennews

Bad Marienberg (www.aktiencheck.de) - Welche Kursziele und Ratings trauen die Analysten der führenden Banken und Research-Häuser der Aktie des biopharmazeutischen…

Gilead Sciences Aktie: Das Pharmaunternehmen auf Rekordkurs? Analysten sehen neue Milliarden-Chance mit Trodelvy

New York (www.aktiencheck.de) - Gilead Sciences-Aktienanalyse von Oppenheimer: Die Analysten von Oppenheimer haben ihr Kursziel für Gilead Sciences Inc. (ISIN: US3755581036,…

Gilead Sciences (GILD) Rises As Market Takes a Dip: Key Facts

In the closing of the recent trading day, Gilead Sciences (GILD) stood at $115.99, denoting a +1.47% change from the…

Why Gilead Sciences Remains A Buy After A 40% Rally

…

Top Stock Reports for Charles Schwab, Gilead Sciences & Medtronic

Todays Research Daily features new research reports on 16 major stocks, including The Charles Schwab Corporation (SCHW), Gilead Sciences, Inc.…

This Company Just Initiated a Quarterly Dividend: Time to Buy?

Biotech giant Renegeron Pharmaceuticals (NASDAQ: REGN) reported its fourth-quarter and full-year 2024 earnings on Feb. 4. The companys results were…

Gilead Sciences, Inc. (GILD) Hit a 52 Week High, Can the Run Continue?

Gilead (GILD) is at a 52-week high, but can investors hope for more gains in the future? We take a…

Why Gilead Sciences Stock Is Jumping Today

Shares of Gilead Sciences (NASDAQ: GILD) were jumping 7.9% higher on Wednesday at 11:34 a.m. The solid gain came after…

Gilead Sciences Aktie: Biotech-Riese steigert Dividende

Kulmbach (www.aktiencheck.de) - Gilead Sciences-Aktienanalyse von "Der Aktionär": Michel Doepke vom Anlegermagazin "Der Aktionär" nimmt in einer aktuellen Aktienanalyse die Aktie…

Gilead Sciences (GILD) is a Top-Ranked Value Stock: Should You Buy?

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Heres why…

Gilead: Starke Zahlen, höhere Dividende – Aktie startet durch

Der amerikanische Biotech-Riese Gilead Sciences hat im Schlussviertel 2024 überraschend stark abgeschnitten. Sowohl Umsatz als auch Ergebnis je Aktie lagen…

Gilead Sciences Aktie: HIV-Geschäft stabil - Wachstum durch neue Produkte

San Francisco (www.aktiencheck.de) - Gilead Sciences-Aktienanalyse von Wells Fargo Advisors: Rating und Kursziel Wells Fargo-Analyst Mohit Bansal hat das Kursziel für die…

Gilead Sciences: Strong Q4 Results And Huge Progress In HIV

…

Gilead Sciences (GILD) Q4 2024 Earnings Call Transcript

GILD earnings call for the period ending December 31, 2024.…

Gilead Sciences, Inc. 2024 Q4 - Results - Earnings Call Presentation

…